0 results


preCARDIA developed an inpatient partially implantable device for treating patients with Acute Decompensated Heart Failure (ADHF). It is based on the invention of Dr. Navin Kapur, Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist, and Director of the Acute Circulatory Support Program at Tufts Medical Center and Dr. Richard Karas, M.D., Ph.D former CSO and former Executive Director Molecular Cardiology Research Institute (MCRI) Tufts Medical Center. The company was acquired by Abiomed in 2021.


The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

SofinnovaMD Start

The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.


The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

SofinnovaIndustrial Biotech

Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.


The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

SofinnovaDigital Medicine

The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.


The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.

Join our mailing list

Keep up to date with our latest news.

Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.